The European Union Observatory for Nanomaterials has released a comprehensive study examining the integration of nanomaterials into flame retardants, revealing their technological promise alongside significant regulatory challenges. While evidence shows these nano-enabled materials excel at condensed-phase fire suppression mechanisms, critical gaps remain in understanding their human health impacts, environmental hazards, and long-term lifecycle behavior. The findings underscore an urgent need for improved

The European Commission has launched an antitrust investigation into Sanofi over allegations that the pharmaceutical giant abused its dominant market position through a misleading communication campaign disparaging a competitor's influenza vaccine. The probe examines whether Sanofi falsely portrayed CSL Seqirus' Fluad vaccine as scientifically inferior while promoting its own Efluelda product to healthcare professionals in Germany and France.

The European Council has adopted a position on targeted amendments to health legislation aimed at streamlining regulations for genetically modified microorganisms and updating organ processing rules to reflect scientific advances. The proposed changes seek to create a more efficient regulatory process for certain GMMs meeting predetermined safety standards while enabling innovative approaches to organ transplantation that could extend the time between procurement and transplant.

The Court of Justice of the European Union has issued a preliminary ruling in Case C-427/24 Diagramm Halbach, establishing critical principles for determining whether products qualify as medical devices under the EU Medical Device Regulation. The judgment clarifies that manufacturer advertising alone does not determine medical device status, and that products must objectively perform medical purposes to fall within the regulatory definition.

The EU Packaging and Packaging Waste Regulation becomes applicable on 12 August 2026, replacing existing directives with a directly applicable regime governing packaging design, documentation, labelling and end-of-life management across the EU market. Life sciences companies manufacturing medical devices, IVDs and pharmaceuticals face significant compliance obligations, with narrow sector-specific exemptions that do not eliminate core requirements for conformity documentation, substance restrictions...

Advocate General Kokott has delivered a significant opinion recommending the annulment of provisions in the revised Urban Waste Water Treatment Directive that require pharmaceutical and cosmetics producers to finance 80% of quaternary wastewater treatment costs. While accepting the legitimacy of the polluter-pays principle, the AG concludes that the EU legislature failed to adequately substantiate the scientific basis for selecting these industries to bear such substantial financial burden.

The EU Data Act's September 2026 deadline introduces a new access-by-design requirement for connected medical devices and related services, but the practical impact may be more limited than manufacturers expect. This analysis examines what life sciences companies must do to comply with both the upcoming milestone and the broader set of obligations that have been in force since September 2025.

On December 16, 2025, the European Commission (the "Commission") published a proposal for a European Biotech Act (the "Proposed Biotech Act" or "Proposal").